![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2008, American Society for Microbiology Oral Health and Systemic Disease, Department of Periodontics, Endodontics and Dental Hygiene, University of Louisville School of Dentistry, Louisville, Kentucky *Corresponding author. Mailing address: University of Louisville School of Dentistry, 501 South Preston Street, Room 204, Louisville, KY 40292. Phone: (502) 852-3175. Fax: (502) 852-5572. E-mail: dfkina01/at/gwise.louisville.edu Received October 24, 2007; Revised November 29, 2007; Accepted February 26, 2008. This article has been cited by other articles in PMC.Abstract Periodontitis is a chronic human inflammatory disease initiated and sustained by dental plaque microorganisms. A major contributing pathogen is Porphyromonas gingivalis, a gram-negative bacterium recognized by Toll-like receptor 2 (TLR2) and TLR4, which are expressed by human gingival epithelial cells (HGECs). However, it is still unclear how these cells respond to P. gingivalis and initiate inflammatory and immune responses. We have reported previously that HGECs produce a wide range of proinflammatory cytokines, including interleukin-6 (IL-6), IL-8, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha (TNF-α), and IL-1β. In this study, we show that IL-1β has a special role in the modulation of other inflammatory cytokines in HGECs challenged with P. gingivalis. Our results show that the increased production of IL-1β correlates with the cell surface expression of TLR4, and more specifically, TLR4-normal HGECs produce fourfold more IL-1β than do TLR4-deficient HGECs after challenge. Moreover, blocking the IL-1β receptor greatly reduces the production of “secondary” proinflammatory cytokines such as IL-8 or IL-6. Our data indicate that the induction of IL-1β plays an important role in mediating the release of other proinflammatory cytokines from primary human epithelial cells following challenge with P. gingivalis, and this process may be an inflammatory enhancement mechanism adopted by epithelial cells. The etiology of periodontal disease is complex, and variance in the human host response to microbial plaque occurs and relates to the host's innate, inflammatory, or immune defense system. It is estimated that over 500 different bacterial species are capable of colonizing the oral cavity; several of these are considered periodontal pathogens and include the gram-negative bacterium Porphyromonas gingivalis (4, 5, 19). The recognition of invariant pathogen molecular structures, termed microbe-associated molecular patterns, is mediated by a set of gene-encoded receptors that are referred to as pattern recognition receptors, which include Toll-like receptors (TLRs). The binding of bacterial products to TLRs results in the activation of signaling molecules that eventually trigger host responses, such as the release of antimicrobial peptides, proinflammatory cytokines, and chemokines (1). It has previously been shown that P. gingivalis is recognized by TLR4 and TLR2 (7) and interacts with gingival epithelial cells (16). We have shown that the activation of TLRs by P. gingivalis induces the release of proinflammatory cytokines from gingival epithelial cells (9). Therefore, it might be expected that a reduction in cellular TLR4 is associated with a reduction in multiple “normal” host responses and, thus, increased susceptibility to chronic inflammatory diseases, including periodontal disease. The response of the innate system in detecting pathogens and triggering the adaptive immune system is crucial. For example, neutrophil recruitment to the site of infection occurs through a chemotactic gradient, including CXC chemokine ligand 8 or interleukin-8 (IL-8), mainly secreted by epithelial cells (15); other proinflammatory cytokines, including IL-6 and tumor necrosis factor alpha (TNF-α) are also secreted by epithelial cells (9). Among the many cytokines implicated (9, 15), IL-1β appears to play a special role in inflammatory modulation. IL-1β is a potent inflammatory cytokine involved in many important cellular functions, such as proliferation, activation, and differentiation (30), and is an important component of the innate immune response (8). IL-1β also induces the chemotaxis of leukocytes by inducing the induction of IL-8 and activating neutrophils for phagocytosis, degranulation, and oxidative burst activity (6). The release of IL-1β is a critical step in inflammation through the induction of other inflammatory cytokines (27). The induction of IL-1β is highly controlled in two stages, (i) the production of proinflammatory IL-1β (pro-IL-1β) after the triggering of TLRs and other cellular receptors and (ii) the cleavage of the precursor pro-IL-1β to mature IL-1β by caspase-1 (24). IL-1β can stimulate the cells producing it in an autocrine fashion through its own receptor, IL-1R (18, 23). It has previously been demonstrated that blocking the IL-1β receptor with anti-IL-1R results in reduced neutrophil recruitment; however, blocking TNF-α did not (22). Here we report that the induced release of IL-1β by P. gingivalis then modulated the production of other inflammatory cytokines, including IL-8, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNF-α, in human primary gingival epithelial cells (HGECs) (TLR4-normal cells). We also demonstrate that this response is attenuated in TLR4-deficient epithelial cells or when TLR4, IL-1R, or caspase-1 activities were inhibited. MATERIALS AND METHODS Cell isolation and culture. With University of Louisville institutional review board approval, we obtained primary HGECs from healthy patients after third-molar extractions. The gingiva was treated with 0.025% trypsin and 0.01% EDTA overnight at 4°C, and HGECs were isolated as described previously (21). The cell suspension was centrifuged at 120 × g for 5 min, and the pellet was suspended in complete medium, i.e., keratinocyte-serum-free medium (K-SFM; Invitrogen, Carlsbad, CA) containing 10 μg/ml of insulin, 5 μg/ml of transferrin, 10 μM of 2-mercaptoethanol, 10 μM of 2-aminoethanol, 10 mM of sodium selenite, 50 μg/ml of bovine pituitary extract, 100 U/ml of penicillin-streptomycin, and 50 ng/ml of Fungizone. The cells were seeded in 60-mm plastic tissue culture plates coated with type I collagen and incubated in 5% CO2 and 95% air at 37°C. When the cells reached subconfluence, they were harvested and subcultured. Normal human bronchial epithelial (NHBE) cells were obtained from Cambrex (Walkersville, MD), and all experiments with NHBE cells were conducted between passages 4 and 5. NHBE cells were grown in medium containing 1 g/liter (5.5 mM) glucose and formulated with bovine pituitary extract, recombinant human epidermal growth factor, hydrocortisone, insulin, epinephrine, tri-iodothyronine, transferrin, gentamicin, amphotericin B, and retinoic acid (BEGM with SingleQuots; Cambrex, Walkersville, MD). However, the cells were challenged with P. gingivalis in the same medium which was used for HGECs. Bacteria. Actinobacillus actinomycetemcomitans strain Y4 and P. gingivalis strain 33277 were kindly provided by D. Demuth, School of Dentistry, Louisville, KY. P. gingivalis was grown at 37°C in Trypticase soy broth supplemented with 1 g of yeast extract, 5 mg of hemin, and 1 mg of menadione per liter under anaerobic conditions of 85% N2, 10% H2, and 5% CO2 for 2 days. A. actinomycetemcomitans strain Y4 was cultured under microaerophilic conditions at 37°C in brain heart infusion (BHI; Difco) medium supplemented with 40 mg of NaHCO3 per liter. Based on a previously calibrated optical density of 1 to determine the proper multiplicity of infection (MOI) and plating experiments to determine viability, we were confident that our bacterial cultures were live and within the log phase. After cultivation, the bacteria were harvested by centrifugation, washed three times in phosphate-buffered saline, and heat inactivated as described previously (15). Cytokine induction assay. Primary HGEC cultures at the fourth passage were harvested, seeded at a density of 0.5 × 105 cells per six-well culture plate (coated with type I collagen), and maintained in 2 ml of K-SFM medium. When they reached confluence, the cells were washed twice with plain K-SFM (no antibiotics or additives) and 2 ml of complete medium was added. When they reached 90 to 100% confluence, the cells were challenged with P. gingivalis (MOI, 100) or A. actinomycetemcomitans (MOI, 100) at 37°C, 5% CO2, for 24 h. In a blocking assay, caspase-1 was inhibited with YVAD-cmk (1 μM; Clontech, Mountain View, CA) for 1 h prior to challenge in epithelial cells treated with Pam3CSK4, an agonist for TLR1/TLR2 (1 μg/ml; InvivoGen); FSL-1, an agonist for TLR2/TLR6 (1 μg/ml; InvivoGen); R837, an agonist for TLR7/TLR8 (5 μg/ml; Invivogen); human recombinant IL-1β (0.2 ng/ml; R&D); or P. gingivalis for 24 h to demonstrate that the production of proinflammatory cytokines is induced by a variety of TLRs and thus is IL-1β modulated. The IL-1β receptor was inhibited with anti-human IL-1R1 antibody or its isotype control immunoglobulin G (IgG) (1 μg/ml; R&D, Minneapolis, MN) prior to 1 h of challenge. In order to determine whether there was any influence of IL-8 on IL-1β production, the cells were challenged with P. gingivalis in the presence or absence of an IL-8-neutralizing antibody (0.2 μg/ml; R&D). Cell culture supernatants were assayed by Luminex 100 technology using a multiplex of five cytokines, including IL-6, IL-8, GM-CSF, and TNF-α (Upstate, NY). IL-1β was assayed by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) in accordance with the manufacturer's protocol. Real-time PCR. Total RNA was extracted from cultured cells by using TRIzol (Invitrogen, Carlsbad, CA) and quantified by spectrometry at 260 and 280 nm. Ten micrograms from each RNA extract was used to perform first-strand cDNA synthesis using the high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA) in a total volume of 100 μl. Real-time PCR was performed by using 100 ng of cDNA with an ABI 7500 system (Applied Biosystems). TaqMan probes, sense and antisense primers for gene expression of human TLR4, IL-1β, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), as an endogenous control, were purchased from Applied Biosystems. We used a universal PCR master mix (Applied Biosystems) to carry out the reactions according to the manufacturer's protocol. Inhibition of TLR4 expression. Primary epithelial cultures at the fourth passage were harvested, seeded at a density of 0.5 × 105 cells per six-well culture plate (coated with type I collagen), and maintained in 2 ml of medium until they reached 50 to 70% confluence. The epithelial cells were transfected with 100 pmol of short interfering TLR4 (siTLR4; Dharmacon, CA) or short interfering laminin (siLaminin; Dharmacon, CA) as an assay control. Briefly, 3 μl of the transfection reagent FuGENE 6 (Roche Applied Science, Indianapolis, IN) was diluted using 95 μl of serum-free medium and then 100 pmol of siTLR4 or siLaminin was added and incubated at room temperature for 15 min. The reaction was performed overnight, and the medium was replaced with fresh medium. The cytokine induction assay was performed after 48 h as mentioned above. Flow cytometry. Human gingival epithelial cells were washed three times with phosphate-buffered saline, and 1 million cells were stained with 1 μg/ml of phycoerythrin conjugated to anti-human TLR4 or to an isotype control, mouse IgG2a (eBioscience, San Diego, CA), in 100 μl total staining buffer. The cells were analyzed by flow cytometry using BD FACSCalibur and CellQuest software. RESULTS Human gingival epithelial cell cultures and TLR4 expression. It has previously been shown that TLR4 deficiencies may detrimentally reduce the innate immune response to pathogenic bacteria (15). We have a bank of more than 40 primary cultures of HGECs and have determined their TLR4 levels by fluorescence-activated cell sorter analysis in both the resting and P. gingivalis-stimulated states. So far, we have detected three HGECs with reduced TLR4 expression at the protein and mRNA levels; these cells are defined as TLR4 deficient in both basal and challenged states. These TLR4-deficient cells are typically, but not exclusively, related to carriage of the Asp299Gly polymorphism in the TLR4 gene (15). We also utilized three different HGECs, defined as TLR4-normal cells. These cells induced the expression of TLR4 following challenge with P. gingivalis. Those cells are harvested from subjects free of systemic diseases and chronic periodontitis. For our experiments, we chose HGEC-9, -11, and -12, (which are primary HGEC cultures with deficiencies in TLR4 expression) and HGEC-2, -5, and -6 (with normal TLR4 expression). P. gingivalis was chosen for the microbial challenge, as it is considered a putative pathogen in periodontal disease and displays interesting signaling mechanisms through TLR2 and TLR4 (7) and the HGECs thus produce a wide range of cytokine responses to P. gingivalis (15). Recognition of pathogenic microorganisms by the innate immune system is crucial for inflammation and to trigger the adaptive immune system to eliminate bacteria (12). We determined TLR4 gene expression in three TLR4-normal HGECs and three TLR4-deficient HGECs after challenge with P. gingivalis. TLR4 expression was down-regulated in the TLR4-deficient cells (HGEC-9, -11, and -12) compared to the expression in the TLR4-normal gingival epithelial cells (HGEC-2, -5, and -6) at the gene level (Fig. (Fig.1A).1A
IL-1β induction in HGECs challenged by P. gingivalis. IL-1β is a potent proinflammatory cytokine and is produced in a variety of cells, including monocytes, following microbial perturbation (17, 27). Therefore, we examined phenotypic differences of TLR4-normal and TLR4-deficient gingival epithelial cells to check the level of IL-1β by challenge with P. gingivalis for 24 h. The transcription level of IL-1β was increased more than fivefold in TLR4-normal cells challenged by P. gingivalis but not in TLR4-deficient cells (Fig. (Fig.2A).2A
Proinflammatory cytokine production was attenuated in TLR4-deficient cells. Furthermore, we examined whether IL-1β was the only cytokine reduced or whether other proinflammatory cytokines, including IL-6, IL-8, TNF-α, and GM-CSF, were also decreased in TLR4-deficient cells compared to the level in normal cells following challenge with P. gingivalis. To address this point, TLR4-normal and TLR4-deficient epithelial cells were challenged with P. gingivalis for 24 h. The production of GM-CSF was minimally increased by treatment with P. gingivalis in TLR4-deficient cells. However, its induction was dramatically induced in TLR4-normal cells following treatment with P. gingivalis for 24 h (Fig. (Fig.3A).3A
We then determined whether TLR4-deficient cells responded normally to other stimuli, including a TLR2 agonist and exogenous human recombinant IL-1β, since it has been demonstrated that P. gingivalis is recognized by TLR4 and TLR2 (7) and the receptor for IL-1β (IL-1R1) shares structural and signaling pathway similarities with Toll-like receptors (28). Therefore, we challenged both cell types with FSL-1 (a TLR2 agonist) or IL-1β for 24 h. The production of IL-8 (Fig. (Fig.4A)4A
TLR4 regulates proinflammatory cytokine production in HGECs. TLR signaling activation is a critical step in inducing proinflammatory cytokines, and TLR4 is involved in P. gingivalis recognition (7). To examine the importance of the TLR4 receptor in the HGEC response to P. gingivalis and to confirm the results shown above, TLR4-normal cells were transfected with short interfering RNA (siRNA) to TLR4, TLR2, or an irrelevant gene (laminin). Initially, we determined the expression of TLR4 and TLR2 following transfection with siTLR2 or siTLR4. In a comparison with control gene (laminin) silencing, TLR4 expression was significantly down-regulated in the cells transfected with siTLR4 after stimulation with P. gingivalis for 24 h (Fig. (Fig.5A).5A
Released IL-1β modulates proinflammatory cytokine induction in an autocrine manner in human epithelial cells. IL-1β is a potent proinflammatory cytokine produced following challenge with P. gingivalis (2), and it is considered to be a major player in the regulation of other inflammatory cytokines, such as IL-6 (10, 29). To examine IL-1β function, we initially confirmed that the IL-1β receptors were expressed by HGECs (data not shown). We determined that the optimal dose of IL-1β was similar to the amount of IL-1β produced by P. gingivalis (as shown in Fig. Fig.5),5
It has previously been shown that caspase-1 activation is a critical step in converting pro-IL-1β into mature IL-1β (20), and we have confirmed above that IL-1β plays an important role in the regulation of other inflammatory cytokines induced by P. gingivalis in HGECs. In order to examine these points further, we inhibited caspase-1 activation with a caspase-1 inhibitor, YVAD-cmk (26), and the cells were challenged with P. gingivalis in the presence or the absence of YVAD-cmk for 24 h. The production of IL-1β was dramatically reduced in the cells challenged with P. gingivalis after blocking caspase-1 activity (with YVAD-cmk) (Fig. (Fig.7A).7A
IL-8 does not modulate inflammation. We previously demonstrated that the level of IL-8 production is far greater than that of the other cytokines produced by epithelial cells (9). We therefore examined whether IL-8 could modulate the production of cytokines, including IL-1β and IL-6, in human epithelial cells. The cells were challenged with P. gingivalis in the presence of a neutralizing antibody to IL-8 or IgG, an isotype control for the antibody. The production of IL-8 was significantly increased by P. gingivalis, but the induction of IL-8 was undetectable in the cells challenged with P. gingivalis in the presence of its neutralizing antibody (Fig. (Fig.9A).9A
IL-1β can modulate inflammation in the cells following TLR activation. Finally, we examined whether cytokine production could be modulated by IL-1β in the cells challenged with a variety of other TLR-specific agonists. In a previous study, we have shown that HGECs express all TLRs except TLR8 (15). Therefore, HGECs were challenged with Pam3CSK4 (TLR1/TLR2 agonist), FSL-1 (TLR2/TLR6 agonist), or R837 (TLR7 agonist) in the presence or absence of a caspase-1 inhibitor, YVAD-cmk, for 24 h. The production of IL-1β was significantly induced by Pam3CSK4, FSL-1, or R837. However, the inhibition of caspase-1 activation resulted in reduced IL-1β induction following the challenge assay (Fig. 10A
DISCUSSION Oral epithelial cells provide a physical barrier against invading pathogens and play an important role in the innate host defenses. Through the perturbation of gingival epithelial cells, P. gingivalis and other periodontal gram-negative bacteria can trigger several complex signaling cascades. These cascades ultimately regulate the transcription of genes for proinflammatory cytokines, chemokines, antimicrobial peptides, apoptosis, and adaptive immune responses and might have a direct effect on disease and the inflammatory processes. Epithelial cells are a first line of defense against pathogens, and although these cells are not as specialized as professional phagocytes in dealing with pathogens, they may play a sentinel role. The cells may use the extracellular secretion of IL-1β to induce other neighboring epithelial cells in an autocrine manner to help amplify the inflammatory, chemokine, and antimicrobial molecules released. Thus, it has quite different purposes and capabilities than the independently active professional phagocytes and, rather, may allow neighboring epithelial cells to act together in a concerted defense against periodontal microbes. P. gingivalis induces a strong proinflammatory cytokine response in gingival epithelial cells (15). We elected to utilize P. gingivalis in our experiments and to use primary epithelial cells in an attempt to mimic more closely the inflammatory in vivo situation relevant in chronic periodontitis. We observed that live P. gingivalis induced apoptosis in HGECs, and at the end of the challenge assay, the cell viability was less than 50% (data not shown). Therefore, the use of heat-killed bacteria allowed the examination of secondary cytokine induction by P. gingivalis. Although other periodontal gram-negative microorganisms are present and important in the periodontal plaque biofilm, we sought to represent periodontal microbial challenge to the periodontal pocket epithelial lining by using heat-killed P. gingivalis. The present data demonstrate that TLR4 plays an important role in the regulation of IL-1β in the cells challenged with P. gingivalis. IL-1β is one of the most potent inflammatory cytokines, and its induction is tightly controlled. Typically, the production of IL-1β is regulated by at least two steps, the first at the transcription level by TLRs and the second at the posttranscriptional level by the inflammasome, which is a protein complex activating caspase-1 (25). Interestingly, it has been demonstrated that the activation of caspase-1 is TLR independent (13). We consistently found that IL-1β expression at the gene level (Fig. (Fig.2A)2A Furthermore, our study clearly shows that by inhibiting caspase-1 activation or the IL-1β receptor with YVAD-cmk or IL-1R1 antibody, respectively, the induction of other proinflammatory cytokines in the cells following treatment with P. gingivalis was reduced. We found that P. gingivalis can induce 0.2 ng/ml of IL-1β in the cells, and adding the same amount of IL-1β to the cell cultures could increase the production of cytokines (Fig. 6A and B In summary, the work presented here supports a model whereby the regulation of secondary proinflammatory cytokine production in epithelial cells is modulated by IL-1β. This result may be important for the gingival crevice, the site where periodontal inflammation is initiated, as P. gingivalis, a representative of the predominantly gram-negative subgingival plaque biofilm, induces IL-1β, which modulates the induction of other proinflammatory cytokines in gingival epithelial cells. Inflammation so initiated then clinically manifests as gingivitis and subsequently as chronic periodontitis. In a more general context, the regulation of IL-1β production may be an effective therapeutic target for the modulation of inflammation in the treatment of such inflammatory diseases as gout or rheumatoid arthritis (3, 22). Acknowledgments This study was supported by grant NIH NIDCR DE017384. Notes Editor: B. A. McCormick Footnotes Published ahead of print on 10 March 2008.REFERENCES 1. Akira, S. 2001. Bacterial infections and Toll-like receptors. Kekkaku 76593-600. (In Japanese.) [PubMed] 2. Andrian, E., D. Grenier, and M. Rouabhia. 2005. Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. J. Cell. Physiol. 204178-183. [PubMed] 3. Burger, D., J. M. Dayer, G. Palmer, and C. Gabay. 2006. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract. Res. Clin. Rheumatol. 20879-896. [PubMed] 4. Chen, H. A., B. D. Johnson, T. J. Sims, R. P. Darveau, B. J. Moncla, C. W. Whitney, D. Engel, and R. C. Page. 1991. Humoral immune responses to Porphyromonas gingivalis before and following therapy in rapidly progressive periodontitis patients. J. Periodontol. 62781-791. [PubMed] 5. Chen, H. A., A. Weinberg, R. P. Darveau, D. Engel, and R. C. Page. 1995. Immunodominant antigens of Porphyromonas gingivalis in patients with rapidly progressive periodontitis. Oral Microbiol. Immunol. 10193-201. [PubMed] 6. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420885-891. [PubMed] 7. Darveau, R. P., T. T. Pham, K. Lemley, R. A. Reife, B. W. Bainbridge, S. R. Coats, W. N. Howald, S. S. Way, and A. M. Hajjar. 2004. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect. Immun. 725041-5051. [PubMed] 8. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 872095-2147. [PubMed] 9. Eskan, M. A., G. Hajishengallis, and D. F. Kinane. 2007. Differential activation of human gingival epithelial cells and monocytes by Porphyromonas gingivalis fimbriae. Infect. Immun. 75892-898. [PubMed] 10. Greten, F. R., M. C. Arkan, J. Bollrath, L. C. Hsu, J. Goode, C. Miething, S. I. Goktuna, M. Neuenhahn, J. Fierer, S. Paxian, N. Van Rooijen, Y. Xu, T. O'Cain, B. B. Jaffee, D. H. Busch, J. Duyster, R. M. Schmid, L. Eckmann, and M. Karin. 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130918-931. [PubMed] 11. Gutiérrez-Venegas, G., P. Kawasaki-Cardenas, S. R. Cruz-Arroyo, M. Perez-Garzon, and S. Maldonado-Frias. 2006. Actinobacillus actinomycetemcomitans lipopolysaccharide stimulates the phosphorylation of p44 and p42 MAP kinases through CD14 and TLR-4 receptor activation in human gingival fibroblasts. Life Sci. 782577-2583. [PubMed] 12. Kaisho, T., and S. Akira. 2000. Critical roles of Toll-like receptors in host defense. Crit. Rev. Immunol. 20393-405. [PubMed] 13. Kanneganti, T. D., M. Lamkanfi, Y. G. Kim, G. Chen, J. H. Park, L. Franchi, P. Vandenabeele, and G. Nunez. 2007. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26433-443. [PubMed] 14. Kimoto, M., K. Nagasawa, and K. Miyake. 2003. Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scand. J. Infect. Dis. 35568-572. [PubMed] 15. Kinane, D. F., H. Shiba, P. G. Stathopoulou, H. Zhao, D. F. Lappin, A. Singh, M. A. Eskan, S. Beckers, S. Waigel, B. Alpert, and T. B. Knudsen. 2006. Gingival epithelial cells heterozygous for Toll-like receptor 4 polymorphisms Asp299Gly and Thr399Ile are hypo-responsive to Porphyromonas gingivalis. Genes Immun. 7190-200. [PubMed] 16. Lamont, R. J., D. Oda, R. E. Persson, and G. R. Persson. 1992. Interaction of Porphyromonas gingivalis with gingival epithelial cells maintained in culture. Oral Microbiol. Immunol. 7364-367. [PubMed] 17. Mariathasan, S., D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W. P. Lee, Y. Weinrauch, D. M. Monack, and V. M. Dixit. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440228-232. [PubMed] 18. McMahan, C. J., J. L. Slack, B. Mosley, D. Cosman, S. D. Lupton, L. L. Brunton, C. E. Grubin, J. M. Wignall, N. A. Jenkins, C. I. Brannan, et al. 1991. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 102821-2832. [PubMed] 19. Persson, G. R., D. Engel, C. Whitney, R. Darveau, A. Weinberg, M. Brunsvold, and R. C. Page. 1994. Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates. Infect. Immun. 621026-1031. [PubMed] 20. Saleh, M. 2006. Caspase-1 builds a new barrier to infection. Cell 1261028-1030. [PubMed] 21. Shiba, H., S. G. Venkatesh, S. U. Gorr, G. Barbieri, H. Kurihara, and D. F. Kinane. 2005. Parotid secretory protein is expressed and inducible in human gingival keratinocytes. J. Periodontal Res. 40153-157. [PubMed] 22. So, A., T. De Smedt, S. Revaz, and J. Tschopp. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9R28. [PubMed] 23. Stylianou, E., L. A. O'Neill, L. Rawlinson, M. R. Edbrooke, P. Woo, and J. Saklatvala. 1992. Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. J. Biol. Chem. 26715836-15841. [PubMed] 24. Sutterwala, F. S., Y. Ogura, M. Szczepanik, M. Lara-Tejero, G. S. Lichtenberger, E. P. Grant, J. Bertin, A. J. Coyle, J. E. Galan, P. W. Askenase, and R. A. Flavell. 2006. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24317-327. [PubMed] 25. Sutterwala, F. S., Y. Ogura, D. S. Zamboni, C. R. Roy, and R. A. Flavell. 2006. NALP3: a key player in caspase-1 activation. J. Endotoxin Res. 12251-256. [PubMed] 26. Taxman, D. J., J. Zhang, C. Champagne, D. T. Bergstralh, H. A. Iocca, J. D. Lich, and J. P. Ting. 2006. Cutting edge: ASC mediates the induction of multiple cytokines by Porphyromonas gingivalis via caspase-1-dependent and -independent pathways. J. Immunol. 1774252-4256. [PubMed] 27. Tschopp, J., F. Martinon, and K. Burns. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 495-104. [PubMed] 28. Xu, Y., X. Tao, B. Shen, T. Horng, R. Medzhitov, J. L. Manley, and L. Tong. 2000. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 408111-115. [PubMed] 29. Xue, M. L., H. Zhu, M. Willcox, D. Wakefield, A. Lloyd, and A. Thakur. 2001. The role of IL-1beta in the regulation of IL-8 and IL-6 in human corneal epithelial cells during Pseudomonas aeruginosa colonization. Curr. Eye Res. 23406-414. [PubMed] 30. Yang, J., W. C. Hooper, D. J. Phillips, and D. F. Talkington. 2003. Interleukin-1beta responses to Mycoplasma pneumoniae infection are cell-type specific. Microb. Pathog. 3417-25. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
J Periodontol. 1991 Dec; 62(12):781-91.
[J Periodontol. 1991]Oral Microbiol Immunol. 1995 Aug; 10(4):193-201.
[Oral Microbiol Immunol. 1995]Infect Immun. 1994 Mar; 62(3):1026-31.
[Infect Immun. 1994]Kekkaku. 2001 Aug; 76(8):593-600.
[Kekkaku. 2001]Infect Immun. 2004 Sep; 72(9):5041-51.
[Infect Immun. 2004]Oral Microbiol Immunol. 1992 Dec; 7(6):364-7.
[Oral Microbiol Immunol. 1992]Infect Immun. 2007 Feb; 75(2):892-8.
[Infect Immun. 2007]Genes Immun. 2006 Apr; 7(3):190-200.
[Genes Immun. 2006]Microb Pathog. 2003 Jan; 34(1):17-25.
[Microb Pathog. 2003]Blood. 1996 Mar 15; 87(6):2095-147.
[Blood. 1996]Nature. 2002 Dec 19-26; 420(6917):885-91.
[Nature. 2002]Nat Rev Mol Cell Biol. 2003 Feb; 4(2):95-104.
[Nat Rev Mol Cell Biol. 2003]Immunity. 2006 Mar; 24(3):317-27.
[Immunity. 2006]J Periodontal Res. 2005 Apr; 40(2):153-7.
[J Periodontal Res. 2005]Genes Immun. 2006 Apr; 7(3):190-200.
[Genes Immun. 2006]Genes Immun. 2006 Apr; 7(3):190-200.
[Genes Immun. 2006]Infect Immun. 2004 Sep; 72(9):5041-51.
[Infect Immun. 2004]Crit Rev Immunol. 2000; 20(5):393-405.
[Crit Rev Immunol. 2000]Nature. 2006 Mar 9; 440(7081):228-32.
[Nature. 2006]Nat Rev Mol Cell Biol. 2003 Feb; 4(2):95-104.
[Nat Rev Mol Cell Biol. 2003]Life Sci. 2006 Apr 25; 78(22):2577-83.
[Life Sci. 2006]Infect Immun. 2004 Sep; 72(9):5041-51.
[Infect Immun. 2004]Nature. 2000 Nov 2; 408(6808):111-5.
[Nature. 2000]Infect Immun. 2004 Sep; 72(9):5041-51.
[Infect Immun. 2004]J Cell Physiol. 2005 Jul; 204(1):178-83.
[J Cell Physiol. 2005]Cell. 2007 Sep 7; 130(5):918-31.
[Cell. 2007]Curr Eye Res. 2001 Dec; 23(6):406-14.
[Curr Eye Res. 2001]Cell. 2006 Sep 22; 126(6):1028-30.
[Cell. 2006]J Immunol. 2006 Oct 1; 177(7):4252-6.
[J Immunol. 2006]Infect Immun. 2007 Feb; 75(2):892-8.
[Infect Immun. 2007]Genes Immun. 2006 Apr; 7(3):190-200.
[Genes Immun. 2006]Genes Immun. 2006 Apr; 7(3):190-200.
[Genes Immun. 2006]J Endotoxin Res. 2006; 12(4):251-6.
[J Endotoxin Res. 2006]Immunity. 2007 Apr; 26(4):433-43.
[Immunity. 2007]Nat Rev Mol Cell Biol. 2003 Feb; 4(2):95-104.
[Nat Rev Mol Cell Biol. 2003]Scand J Infect Dis. 2003; 35(9):568-72.
[Scand J Infect Dis. 2003]Best Pract Res Clin Rheumatol. 2006 Oct; 20(5):879-96.
[Best Pract Res Clin Rheumatol. 2006]Arthritis Res Ther. 2007; 9(2):R28.
[Arthritis Res Ther. 2007]